Pharmacy Times
DECEMBER 24, 2024
The monoclonal antibody demonstrates the ability to reduce the incidence and improve symptoms related to sleep disorders and psychiatric disorders such as anxiety.
Drug Topics
DECEMBER 24, 2024
Check out this list of our top 5 most read COVID-19 stories from the year 2024.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
DECEMBER 23, 2024
Check out this list of our top 5 most read Drug Topics stories from the year 2024.
The Checkup by Singlecare
DECEMBER 20, 2024
Mixing alcohol with metoprolol can come with various side effects, some of which can be serious. Many people take metoprolol, either as metoprolol tartrate or metoprolol succinate , to help manage high blood pressure and heart conditions. If youre considering drinking alcohol while taking this prescription drug, you should know the possible risks. For some people who know how they react to the medication and alcohol, drinking in moderation may be doable.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
DECEMBER 24, 2024
The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.
STAT
DECEMBER 20, 2024
Novo Nordisk’s next-generation obesity candidate led patients to lose a substantial amount of weight in a pivotal study but fell short of expectations, results that cast into doubt the future competitiveness of the company in the booming weight loss market. The treatment, called CagriSema, led patients to lose 20% of their weight at 68 weeks in a late-stage study when looking at all participants, including those who dropped out, Novo said Friday.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
DECEMBER 24, 2024
Pharmacists can significantly improve chronic obstructive pulmonary disease (COPD) management by promoting non-pharmacological interventions.
The Checkup by Singlecare
DECEMBER 23, 2024
In a world where the battle against obesity and diabetes is more pressing than ever, a groundbreaking medication is making waves for its dual capabilities. Ozempic (active ingredient semaglutide), a prescription medication manufactured by Novo Nordisk, is approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar in patients with Type 2 diabetes.
Pharmaceutical Technology
DECEMBER 23, 2024
Lillys Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.
Compounding Pharmacy of America
DECEMBER 23, 2024
Learn how compounding pharmacies ensure safety and reliability through rigorous standards, sterile preparations, and personalized solutions for unique healthcare needs. The post Are Compounding Pharmacies Safe? Everything You Need to Know appeared first on Compounding Pharmacy of America.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
DECEMBER 20, 2024
Zepbound from Eli Lilly is the first and only prescription medicine approved by the FDA for adults with obstructive sleep apnea and obesity.
Pharmacy Times
DECEMBER 24, 2024
Despite the explosion of public interest in these drugs, ongoing shortages and debates over compounding made access difficult.
Fierce Pharma
DECEMBER 23, 2024
The company already moved to cut its entire commercial sales force following several FDA setbacks in its efforts to introduce sotagliflozin in diabetes.
pharmaphorum
DECEMBER 24, 2024
AstraZeneca's EGFR inhibitor Tagrisso has become the first drug in the class to be approved in the EU for a form of early-stage lung cancer.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Med Ed 101
DECEMBER 22, 2024
I’ve put together an approximately 20-minute video on the BCMTMS exam and what you can expect for 2025. General information on the 2025 BCMTMS Exam Who writes the exam? – National Board of Medication Therapy Management Eligibility ASK EMPLOYER IF THEY WILL HELP PURCHASE STUDY MATERIALS AND TEST COSTS!!!! About The BCMTMS Exam Content Domains […] The post 2025 BCMTMS Exam – How To Prepare?
Pharmacy Times
DECEMBER 24, 2024
In this episode of Public Health Matters, Christina Madison discusses the concept of reproductive justice and ensuring Black maternal health efforts are not left behind with Regina Davis Moss of In Our Own Voice.
Fierce Pharma
DECEMBER 23, 2024
The FDA approved Novo Nordisk's tissue factor pathway inhibitor (TFPI) antagonist concizumab as a once-a-day treatment to prevent or curb the frequency of bleeding episodes in patients ages 12 and older who have hemophilia A or B with inhibitors. The green light follows a rejection in 2023 and a trial pause over safety concerns several years before that.
pharmaphorum
DECEMBER 24, 2024
AstraZeneca and Daiichi Sankyo have decided to voluntarily withdraw their EU marketing application for Dato-DXd in lung cancer.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
DECEMBER 20, 2024
HHS released a list of 64 drugs on Friday that will have reduced co-insurance for patients with Medicare Part B. The discounts come from the Inflation Reduction Act which requires drug makers to give rebates to the federal government when a drug's cost rises more than inflation.
Drug Topics
DECEMBER 23, 2024
Researchers reviewed Medicaid policies to understand vaccine coverage and reimbursement rates among physicians and pharmacists.
Pharmacy Times
DECEMBER 24, 2024
Pharmacists are encouraged to work closely with health care providers to ensure appropriate use of high-cost Intravenous immunoglobulin (IVIG) therapy for BK nephropathy.
STAT
DECEMBER 27, 2024
Vijay Yeldandia was an energetic and rambunctious toddler when he was growing up in India. But at the age of two, he came down with polio and became paralyzed from the neck down. Over time, “I learned how to walk with braces and crutches,” recalls Yeldandia, now a professor of medicine and surgery at the University of Illinois Chicago who is primarily based in India.
pharmaphorum
DECEMBER 24, 2024
Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines.
Fierce Healthcare
DECEMBER 23, 2024
Despite significant headwinds coming to bear over the past several years, healthcare executives are expecting a favorable 2025, according to a new survey from Deloitte.
Drug Topics
DECEMBER 26, 2024
Check out this list of our top 5 most read cardiology stories from the year 2024.
Pharmacy Times
DECEMBER 23, 2024
The approval of the generic to liraglutide injection, currently in shortage, could help increase patient access to the type 2 diabetes treatment.
Fierce Pharma
DECEMBER 20, 2024
Perhaps PD-1 inhibitors just arent for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all.
pharmaphorum
DECEMBER 24, 2024
The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.
STAT
DECEMBER 27, 2024
A woman sat in our emergency department in agonizing pain, feeling shaky, nauseous, and weak — drug withdrawal was setting in. But she wasn’t a “junkie” or even a recreational drug user. She was in her mid-60s with advanced cancer in her ovaries that had spread to her abdomen, causing unbearable pain. She was my patient — let’s call her Teresa.
Drug Topics
DECEMBER 25, 2024
Check out this list of our top 5 most read digestive health stories from the year 2024.
Pharmacy Times
DECEMBER 24, 2024
Factors associated with intravenous immunoglobulin (IVIG)-related adverse events include older age, dehydration, and administration of multiple IVIG infusions.
The Guardian - Pharmaceutical Industry
DECEMBER 25, 2024
Guardian review finds many online pharmacies flouting strict advertising rules that govern prescription-only drugs Weight-loss injections are being aggressively marketed to British consumers through often illegal promotions, in a practice experts have described as a wild west industry of drug selling. The booming market for jabs such as Wegovy and Mounjaro has triggered a price battle among online pharmacies, with even high-street chains cashing in on the soaring demand.
Fierce Pharma
DECEMBER 23, 2024
The FDA has approved Vertexs Alyftrek, a once-daily triple combination for the treatment of cystic fibrosis. But analysts have different views on how the switch from Vertex's twice-daily Trikafta will play out.
Expert insights. Personalized for you.
145 
Let's personalize your content